Avalon GloboCare Submits Listing Application for The NASDAQ Capital Market

FREEHOLD, NJ -- (Marketwired) -- 03/19/18 -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today it has filed an application for listing on the NASDAQ Capital Market®.

"Over the past year, we have made significant strides in developing and commercializing innovative and transformative cell-based technologies. We believe we are well positioned to continue our growth and our plans to list on the Nasdaq Capital Market should provide us greater exposure as we execute on upcoming milestones," stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp.

Boustead Securities' Dan McClory, Managing Director and Head of Equity Capital Markets, commented, "Avalon is developing disruptive technologies for the cell therapy and regenerative medicine markets. We look forward to supporting Avalon through the listing process, which should enhance awareness of Avalon within the investment community and help build a broader, more diverse shareholder base over time."

About Avalon GloboCare Corp.
Avalon GloboCare Corp. (OTCQB: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine. For more information, please visit www.avalon-globocare.com.

Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The fact that the Company has submitted its application for listing its shares on the NASDAQ does not suggest the listing will be ultimately approved by the NASDAQ. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 South Street, Suite 3100
Freehold, New Jersey 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020
avco@crescendo-ir.com

Source: Avalon GloboCare Corp.

Released March 19, 2018